Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + HAG for relapsed/refractory adult T-ALL/LBL
ChiCTR2400092114Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission rate (CR/CRi). Planned start Nov 2024; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR2400092114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092114.